AU2016254150B2 - Specific detection of clusterin isoforms - Google Patents

Specific detection of clusterin isoforms Download PDF

Info

Publication number
AU2016254150B2
AU2016254150B2 AU2016254150A AU2016254150A AU2016254150B2 AU 2016254150 B2 AU2016254150 B2 AU 2016254150B2 AU 2016254150 A AU2016254150 A AU 2016254150A AU 2016254150 A AU2016254150 A AU 2016254150A AU 2016254150 B2 AU2016254150 B2 AU 2016254150B2
Authority
AU
Australia
Prior art keywords
clusterin
kidney
specifically bind
isoforms
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016254150A
Other languages
English (en)
Other versions
AU2016254150A1 (en
Inventor
John Joseph Quinn
Murthy Vsn Yerramilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of AU2016254150A1 publication Critical patent/AU2016254150A1/en
Application granted granted Critical
Publication of AU2016254150B2 publication Critical patent/AU2016254150B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2016254150A 2015-04-30 2016-04-29 Specific detection of clusterin isoforms Active AU2016254150B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155175P 2015-04-30 2015-04-30
US62/155,175 2015-04-30
PCT/US2016/030075 WO2016176565A1 (en) 2015-04-30 2016-04-29 Specific detection of clusterin isoforms

Publications (2)

Publication Number Publication Date
AU2016254150A1 AU2016254150A1 (en) 2017-10-26
AU2016254150B2 true AU2016254150B2 (en) 2021-09-30

Family

ID=56069221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016254150A Active AU2016254150B2 (en) 2015-04-30 2016-04-29 Specific detection of clusterin isoforms

Country Status (12)

Country Link
US (1) US20180142009A1 (enExample)
EP (2) EP4019976A1 (enExample)
JP (2) JP6948265B2 (enExample)
KR (1) KR102462056B1 (enExample)
CN (1) CN108093648B (enExample)
AU (1) AU2016254150B2 (enExample)
CA (1) CA2983828A1 (enExample)
DK (1) DK3289363T3 (enExample)
ES (1) ES2907068T3 (enExample)
MX (1) MX388832B (enExample)
WO (1) WO2016176565A1 (enExample)
ZA (1) ZA201707313B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3289363T3 (da) * 2015-04-30 2022-02-28 Idexx Lab Inc Specifik påvisning af clusterin isoformer
EP3232200A1 (en) 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Methods and kits for the diagnosis and risk stratification of patients with ischemia
FR3069156B1 (fr) 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
CN109239362B (zh) * 2018-10-22 2021-05-07 西北大学 一种凝集素探针组合在基于尿蛋白糖型鉴别秦岭川金丝猴妊娠方面的应用
CN110045127A (zh) * 2019-04-03 2019-07-23 中国医学科学院北京协和医院 一种IgG4相关性疾病多器官受累的生物标志物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
WO2012102963A1 (en) * 2011-01-26 2012-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
WO2014197729A1 (en) * 2013-06-05 2014-12-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP2714664B2 (ja) * 1988-04-13 1998-02-16 塩野義製薬株式会社 マイコプラズマ由来マクロファージ活性化因子
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
EP1877796A2 (en) * 2005-05-05 2008-01-16 Philadelphia Health & Education Corporation d/b/a Diagnosis of liver pathology through assessment of protein glycosylation
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8168396B2 (en) * 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
DK3289363T3 (da) * 2015-04-30 2022-02-28 Idexx Lab Inc Specifik påvisning af clusterin isoformer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
WO2012102963A1 (en) * 2011-01-26 2012-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
WO2014197729A1 (en) * 2013-06-05 2014-12-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAMES T. KAPRON ET AL, "Identification and characterization of glycosylation sites in human serum clusterin", PROTEIN SCIENCE, (1997-10-01), vol. 6, no. 10, doi:10.1002/pro.5560061007, ISSN 0961-8368, pages 2120 - 2133 *
PROCHNOW, H. et al., "Non-Secreted Clusterin Isoforms Are Translated in Rare Amounts from Distinct Human mRNA Variants and Do Not Affect Bax-Mediated Apoptosis or the NF-κB Signaling...", PLOS One, 2013, Vol. 8, Issue 9, e75303, pages 1-15 *

Also Published As

Publication number Publication date
AU2016254150A1 (en) 2017-10-26
KR20180003549A (ko) 2018-01-09
NZ736200A (en) 2021-11-26
EP3289363A1 (en) 2018-03-07
CN108093648A (zh) 2018-05-29
CA2983828A1 (en) 2016-11-03
ES2907068T3 (es) 2022-04-21
JP6948265B2 (ja) 2021-10-13
US20180142009A1 (en) 2018-05-24
MX2017013729A (es) 2018-05-22
ZA201707313B (en) 2022-02-23
JP2021099342A (ja) 2021-07-01
EP4019976A1 (en) 2022-06-29
BR112017021850A2 (pt) 2018-07-10
EP3289363B1 (en) 2021-11-24
CN108093648B (zh) 2020-04-10
DK3289363T3 (da) 2022-02-28
MX388832B (es) 2025-03-20
KR102462056B1 (ko) 2022-11-02
WO2016176565A1 (en) 2016-11-03
JP2018515762A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
AU2016254150B2 (en) Specific detection of clusterin isoforms
US12385925B2 (en) Anti-VLA-4 related assays
JP6074846B2 (ja) 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
KR101495225B1 (ko) Ast 양의 측정을 통한 간 질환 진단, 예후 또는 모니터링 키트 및 방법
ES2744175T3 (es) Biomarcadores suPAR no glucosilados y usos de los mismos
US9291629B2 (en) Adiponectin receptor C-terminal fragments (CTF)-immunoglobulin
NZ736200B2 (en) Specific detection of clusterin isoforms
JP2025505396A (ja) 進行性慢性腎疾患を安定慢性腎疾患と区別するための方法及び組成物
BR112017021850B1 (pt) Métodos para detectar clusterina específica do rim, doença renal, insuficiência renal ou danos nos rins, para distinguir mais uma isoforma de clusterina a partir de outros tipos de isoformas dela e para melhorar a detecção de clusterina e de isoformas dela, kit e complexo
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
JP6829357B2 (ja) 抗体の糖鎖検出法
JP5087767B2 (ja) βカゼインによって認識される複合体とその癌診断への応用
KR101174736B1 (ko) 대장암 진단 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)